Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025

Rhea-AI Summary

Longeveron (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company, has announced its participation in the upcoming Emerging Growth Virtual Conference. The company, which focuses on developing cellular therapies for life-threatening and chronic aging-related conditions, will present on February 19, 2025, from 3:10 to 3:20 p.m. ET.

Interested parties can access the presentation through the 'Events and Presentations' section of Longeveron's website. The webcast replay will remain available for 180 days after the conference. Questions can be submitted in advance to Questions@EmergingGrowth.com or asked during the live event.

News Market Reaction

+6.37%

1 alert

+6.37% News Effect

On the day this news was published, LGVN gained 6.37%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

MIAMI, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the Emerging Growth Virtual Conference taking place February 18-19, 2025.

Details for the Company’s presentation:

Date:	February 19, 2025
Time:	3:10 – 3:20 p.m. ET

The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 180 days following the conference.

Questions may be submitted in advance to Questions@EmergingGrowth.com or asked during the event.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B^TM development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

FAQ

When is Longeveron (LGVN) presenting at the Emerging Growth Virtual Conference?

Longeveron (LGVN) is presenting at the Emerging Growth Virtual Conference on February 19, 2025, from 3:10 to 3:20 p.m. ET.

How long will the LGVN conference presentation replay be available?

The webcast replay will be available on Longeveron's website for 180 days following the conference.

How can investors submit questions for Longeveron's (LGVN) presentation?

Investors can submit questions in advance to Questions@EmergingGrowth.com or ask them during the live event.

Where can investors access Longeveron's (LGVN) Emerging Growth Conference presentation?

Investors can access the presentation through the 'Events and Presentations' section of Longeveron's website.